NCT06887270View on ClinicalTrials.gov

Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Anticoagulant-induced BleedingDirect Oral AnticoagulantCancerCentral Venous CatheterPeriprocedural Complication
Interventions
OTHER

Continued DOAC

The continued DOAC group will continue their DOAC peri-procedurally as routine without interruption.

OTHER

Interrupted DOAC

The interrupted DOAC group will take their last DOAC dose on Day -2, unless their DOAC is Dabigatran and their creatinine clearance is \< 50mL/min (Cockcroft-Gault equation), in which their last dose will be on Day -3. The DOAC will be resumed on Day +1.

Trial Locations (1)

M5G 2C4

University Health Network, Toronto

Sponsors

Collaborators (1)

Helliwell Foundation
All Listed Sponsors
collaborator

Helliwell Foundation

UNKNOWN

lead

University Health Network, Toronto

OTHER